Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): A trial of the eastern cooperative oncology group

Cancer

Volumn 110, Issue 4, 2007, Pages 759-763

  Dreicer, Robert ^a   Li, Shuli ^b   Manola, Judith ^b   Haas, Naomi B ^c   Roth, Bruce J ^d   Wilding, George ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Ixabepilone; Phase 2 trial; Urothelial carcinoma

Indexed keywords

DOCETAXEL; EPOTHILONE B; IXABEPILONE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GRANULOCYTOPENIA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; KAPLAN MEIER METHOD; KIDNEY FAILURE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SENSORY NEUROPATHY; SOFT TISSUE METASTASIS; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; AGRANULOCYTOSIS; CARCINOMA, TRANSITIONAL CELL; EPOTHILONES; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 34547865354     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22839     Document Type: Article

References (23)

1. von der Maase H, Hansen S, Roberts J, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-3077.
2. Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 1994;12:2264-2270.
3. Sweeney C, Roth B, Kabbinavar F, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006;24:3451-3457.
4. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997;15:1853-1857.
5. Bamias A, Aravantinos G, Deliveliotis C, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22:220-228.
6. Raghavan D. Advanced bladder and urothelial cancers. Eur J Cancer. 2000;36(Suppl 2):1-6.
7. Witte RS, Elson P, Bono B, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol. 1997;15:589-593.
8. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. J Clin Oncol. 1997;15:2449-2455.
9. Krege S, Rembrink V, Borgermann CH, Otto T, Rubben H. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J Urol. 2001;165:67-71.
10. Goodin S, Kane M, Rubin E. Epothilones: mechanism of action and biologic activity. J Clin Oncol. 2004;22:2015-2025.
11. Kowalski R, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol). J Biol Chem. 1997;272:2534-2541.
12. Lee F, Borzilleri R, Fairchild C, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7:1429-1437.
13. Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res. 2004;10:1289-1298.
14. Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol. 2003;21:1866-1873.
15. McDaid H, Mani S, Shen H-J, Muggia F, Sonnichsen D, Horwitz S. Validation of the pharmacodynamics of BMS-247550, an analog of epothilone B, during a phase I clinical study. Clin Can Res. 2002;8:2035-2043.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
17. Bajorin D, Dodd P, Mazumdar M, et al. Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173-3181.
18. International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party,EORTC Genito-Urinary Group,Australian Bladder Cancer Study Group,National Cancer Institute of Canada Clinical Trials Group,Finnbladder, Norwegian Bladder Cancer Study Group, et al. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet. 1999;354:533-540.
19. Grossman H, Natale R, Tangen C, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859-866.
20. Sweeney CJ, Williams SD, Finch DE, et al. A phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer. 1999;86:514-518.
21. Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 2001;92:2993-2998.
22. Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer. 2006;94:1395-1401.
23. Hussain MH, Tangen C, Lara P, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol. 2005;23:8724-8729.